NASDAQ: MDXHMdxhealth Sa Stock
$2.30-0.07 (-2.95%)
Updated Apr 17, 2024
MDXH Price
$2.30
Fair Value Price
N/A
Market Cap
$6.22M
52 Week Low
$2.15
52 Week High
$4.64
P/E
-0.14x
P/B
0.86x
P/S
0.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$70.19M
Earnings
-$43.10M
Gross Margin
62.6%
Operating Margin
-38.93%
Profit Margin
-61.4%
Debt to Equity
16.92
Operating Cash Flow
-$21M
Beta
0.4
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MDXH Overview
MDxHealth SA (formerly OncoMethylome Sciences SA) provides urologic solutions in the U.S. and internationally. OFferings include SelectMDx (a prostate cancer genomic testing solution), a non-invasive urine test, and ConfirmMDx, an epigenetic test that provide a clinical pathway to identify clinically prostate cancer using mimimally invasive procedures. MDxHealth was incorporated in 2003 and is headquartered in Herstal, Belgium.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDXH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDXH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDXH is good value based on its book value relative to its share price (0.86x), compared to the US Diagnostics & Research industry average (4.05x)
P/B vs Industry Valuation
MDXH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MDXH due diligence checks available for Premium users.
Be the first to know about important MDXH news, forecast changes, insider trades & much more!
MDXH News
Valuation
MDXH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
36.63x
Market
41.64x
MDXH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
4.05x
MDXH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDXH's financial health
Profit margin
Revenue
$19.4M
Net Income
-$10.7M
Profit Margin
-55.3%
MDXH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MDXH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$129.1M
Liabilities
$121.9M
Debt to equity
16.92
MDXH's short-term assets ($38.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDXH's long-term liabilities ($102.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDXH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$676.0k
Financing
-$2.3M
MDXH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDXH vs Diagnostic & Research Stocks
Mdxhealth Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.